Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan

[1]  K. Nogami,et al.  Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A , 2021, Thrombosis and Haemostasis.

[2]  K. Nogami,et al.  A microchip flow‐chamber assay screens congenital primary hemostasis disorders , 2020, Pediatrics international : official journal of the Japan Pediatric Society.

[3]  Tomoko Matsumoto,et al.  An anti‐factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A , 2020, Journal of thrombosis and haemostasis : JTH.

[4]  K. Nogami,et al.  Clot waveform analysis using CS‐2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  K. Nogami,et al.  Possible assessment of coagulation function and haemostasis therapy using comprehensive coagulation assays in a patient with acquired haemophilia A , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  K. Nogami,et al.  Assessing the clinical severity of type 1 von Willebrand disease patients with a microchip flow‐chamber system , 2016, Journal of thrombosis and haemostasis : JTH.

[7]  J. Griffin,et al.  Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa , 2015, Thrombosis and Haemostasis.

[8]  R. Greil,et al.  Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. , 2015, Blood.

[9]  A. Tiede,et al.  Laboratory Diagnosis of Acquired Hemophilia A: Limitations, Consequences, and Challenges , 2014, Seminars in Thrombosis & Hemostasis.

[10]  K. Nogami,et al.  Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis , 2014, Journal of thrombosis and haemostasis : JTH.

[11]  Massimo Franchini,et al.  Acquired haemophilia A: A 2013 update , 2013, Thrombosis and Haemostasis.

[12]  Tomoko Matsumoto,et al.  Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis , 2013, Thrombosis and Haemostasis.

[13]  F. Pellegrini,et al.  Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. , 2012, Blood.

[14]  G. Rivard,et al.  Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  J. Esser,et al.  Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) , 2012, Journal of thrombosis and haemostasis : JTH.

[16]  Tomoko Matsumoto,et al.  A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies , 2012, Thrombosis and Haemostasis.

[17]  D. Grobbee,et al.  Clinical severity of haemophilia A: does the classification of the 1950s still stand? , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  P. Collins,et al.  Management of acquired haemophilia A , 2011, Journal of thrombosis and haemostasis : JTH.

[19]  M. Gebbink.  Tissue‐type plasminogen activator‐mediated plasminogen activation and contact activation, implications in and beyond haemostasis , 2011, Journal of thrombosis and haemostasis : JTH.

[20]  C. Kessler,et al.  International recommendations on the diagnosis and treatment of patients with acquired hemophilia A , 2009, Haematologica.

[21]  H. Lijnen,et al.  New insights into the molecular mechanisms of the fibrinolytic system , 2009, Journal of thrombosis and haemostasis : JTH.

[22]  G. Lippi,et al.  Acquired factor VIII inhibitors. , 2008, Blood.

[23]  T. Baglin,et al.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. , 2007, Blood.

[24]  A. Giles,et al.  The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay , 2006, Journal of thrombosis and haemostasis : JTH.

[25]  A. Lienhart,et al.  Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  N. Booth,et al.  Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI , 2003, Journal of thrombosis and haemostasis : JTH.

[27]  J. Astermark,et al.  Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation Assay , 2003, Pathophysiology of Haemostasis and Thrombosis.

[28]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[29]  J. Delgado,et al.  Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors , 2003, British journal of haematology.

[30]  K. Nogami,et al.  Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis. , 2001, Blood.

[31]  C. Kessler,et al.  9 Acquired inhibitors , 1996 .

[32]  J. Sixma,et al.  The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A , 1984, British journal of haematology.

[33]  K. Lechner,et al.  A Survey of 215 Non-Hemophilic Patients with Inhibitors to Factor VIII , 1981, Thrombosis and Haemostasis.

[34]  G. Zampighi,et al.  Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. , 1981, Biochemistry.

[35]  D. Green,et al.  Proceedings: A more uniform measurement of factor VIII inhibitors. , 1975, Thrombosis et diathesis haemorrhagica.

[36]  Tomoko Matsumoto,et al.  First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillin , 2017, International Journal of Hematology.

[37]  C. Kessler,et al.  Acquired inhibitors. , 1996, Bailliere's clinical haematology.

[38]  S. Mehta,et al.  Acquired haemophilia. , 1990, The Journal of the Association of Physicians of India.